

Vaccination Report – 24 May 2022

1. Vaccine Implementation

- WHO's Emergency Use Listing(EUL) Vaccines (Last Updated 2 April 2022)

| | Manufacturer | Name of Vaccine | NRA of Record | Vaccine type |
|----|----------------------------------|--|---|--------------------------------------|
| 1 | Pfizer-BioNTech (US) | BNT162b2/COMIRNATY Tozinameran (INN) | EMA,USFDA | mRNA |
| 2 | AstraZeneca (UK) | AZD1222 Vaxzevria | EMA, MFDS KOREA, Japan MHLW/PMDA, Australia TGA, COFEPRIS(Mexico), ANMAT(Argentina) | Non ReplicatingViral vector |
| 3 | Serum Institute of India (India) | Covishield (ChAdOx1_nCoV-19) | DCGI | Non Replicating Viral Vector |
| 4 | Johnson &Johnson (US) | Ad26.CoV2.S | EMA, DCGI | Non ReplicatingViral vector |
| 5 | Moderna (US) | mRNA-1273 | EMA, USFDA, MFDS | mRNA |
| 6 | Sinopharm Beijing (China) | SARS-CoV-2 Vaccine(Vero Cells) | NMPA | Inactivated virus (Vero Cells) |
| 7 | Sinovac (China) | COVID-19 Vaccine (Vero Cells) | NMPA | Inactivated virus (Vero Cell) |
| 8 | Bharat Biotech (India) | SARS-CoV-2 Vaccine, Inactivated (Vero Cell)/ COVAXIN | DCGI | Whole-Virion Inactivated (Vero Cell) |
| 9 | Serum Institute of India (India) | NVX-CoV2373/Covovax | DCGI | Protein Subunit |
| 10 | NOVAVAX (US) | NVX-CoV2373/Covovax | EMA | Protein Subunit |

- **38** Vaccines Approved by at Least One Country

| Vaccine Type | mRNA | Non Replicating Viral vector | Inactivated virus | Protein Subunit | DNA | Virus-like Particles (VLP) | Total |
|--------------|------|------------------------------|-------------------|-----------------|-----|----------------------------|-----------|
| In Use | 3 | 7 | 11 | 15 | 1 | 1 | 38 |

Source: <https://covid19.trackvaccines.org/vaccines/> (Last Updated 23 May 2022)

- Vaccination against COVID-19 has now started in **218** locations (Source: Our World in Data. Last Updated 23 May 2022)


| Location | Doses Given | Complete Initial Protocol (% of population) | Partly Vaccinated (% of population) |
|-----------|---------------|---|-------------------------------------|
| Worldwide | 11.77 billion | 4.71 billion (59.85 %) | 5.18 billion (65.74 %) |

About this data:

- a: This data changes rapidly and might not reflect doses still being reported. It may differ from other sites & sources.
- b: Where data for full vaccinations is available, it shows how many people have received at least 1 dose and how many people have been fully vaccinated (which may require more than 1 dose). Where data for full vaccinations isn't available, the data shows the total number of vaccine doses given to people. Since some vaccines require more than 1 dose, the number of fully vaccinated people is likely lower.
- c: It only has full vaccination totals in some locations.

Share of people vaccinated against COVID-19, May 23, 2022

Our World in Data



Source: Official data collated by Our World in Data


Note: Alternative definitions of a full vaccination, e.g. having been infected with SARS-CoV-2 and having 1 dose of a 2-dose protocol, are ignored to maximize comparability between countries.

CC BY

Share of people who completed the initial COVID-19 vaccination protocol, May 23, 2022

Our World in Data

Total number of people who received all doses prescribed by the initial vaccination protocol, divided by the total population of the country.




Source: Official data collated by Our World in Data – Last updated 24 May 2022

OurWorldInData.org/coronavirus • CC BY

Note: Alternative definitions of a full vaccination, e.g. having been infected with SARS-CoV-2 and having 1 dose of a 2-dose protocol, are ignored to maximize comparability between countries.

COVID-19 vaccine boosters administered per 100 people, May 23, 2022

Total number of vaccine booster doses administered, divided by the total population of the country. Booster doses are doses administered beyond those prescribed by the original vaccination protocol.




Source: Official data collated by Our World in Data – Last updated 24 May 2022

OurWorldInData.org/coronavirus • CC BY

COVID-19 vaccination policy, May 23, 2022

Policies for vaccine delivery. Vulnerable groups include key workers, the clinically vulnerable, and the elderly. "Others" include select broad groups, such as by age.



Source: Oxford COVID-19 Government Response Tracker, Blavatnik School of Government, University of Oxford – Last updated 24 May 2022
OurWorldInData.org/coronavirus • CC BY

2. Vaccine effectiveness against symptomatic infection for Alpha, Delta and Omicron variants

| Vaccine Status | Vaccine Effectiveness | | |
|--------------------------------------|--|--|---------|
| | Alpha | Delta | Omicron |
| 1 Dose (BNT162b2 or ChAdOx1 nCoV-19) | 48.7% (95%CI: 45.5-51.7%) ¹ 66%(BNT162b2) ⁴ 64% (ChAdOx1) ⁴ | 30.7% (95%CI: 25.2-35.7%) ¹ 56%(BNT162b2) ⁴ 67%(ChAdOx1) ⁴ 82% (95% CI:73- 91%) ⁷ | |
| 1 Dose (mRNA-1273) | 83% ⁴ | 72% ⁴ | |
| 1 Dose(Sinopharm or Sinovac) | | 13.8%,(95%CI: -60.2-54.8%) ³ | |

| | | | |
|---|---|---|--|
| 2 Doses (BNT162b2) | 93.7% (95%CI: 91.6-95.3) ¹ 76% (95%CI: 69-81%) ² 89% ⁴ | 88% (95%CI: 85.3-90.1%) ¹ 42% (95% CI: 13-62%) ² 87% ⁴ 93% (95% CI: 88-97%/12-18Y) ⁵ 93% (95% CI: 88-97%) ⁷ | 50% (95% CI: 35%–62%) ⁸ |
| 2 Doses (ChAdOx1 nCoV-19) | 74.5% (95%CI: 68.4-79.4%) ¹ | 67.0% (95%CI: 61.3-71.8%) ¹ | |
| 2 Doses (mRNA-1273) | 86% , (95%CI: 81-90.6%) ² | 76% , (95% CI: 58-87%) ² | 30.4% (95% CI: 5.0%-49.0%) ⁹ |
| 2 Doses(Sinopharm or Sinovac) | | 59.0% , (95%CI: 16.0-81.6%) ³ | |
| 3 Doses (BNT162b2) | | 95.33% (SD 6.44) ⁶ 86.1% (95% CI, 67.3 to 94.1) ¹¹ | 67.2% (95% CI: 66.5- 67.8%) at 2 to 4 weeks ¹⁰ 49.4% (95% CI, 47.1 to 51.6) ¹¹ |
| 3 Doses(mRNA-1273) | | | 62.5% (95% CI: 56.2-67.9%) ⁹ 47.3% (95% CI, 40.7 to 53.3) ¹¹ |
| 2 Doses (BNT162b2) + 1Dose(mRNA-1273) | | | 73.9% (95% CI: 73.1- 74.6%) at 2 to 4 weeks ¹⁰ |
| 2 Doses(ChAdOx1 nCoV-19)+1Dose(BNT162b2) | | | 62.4% (95% CI, 61.8- 63.0) at 2 to 4 weeks ¹⁰ |
| 2 Doses (ChAdOx1 nCoV-19)+ 1Dose (mRNA-1273) | | | 70.1% (95% CI, 69.5 to 70.7) at 2 to 4 weeks ¹⁰ |

References:

- 1) [Effectiveness of Covid-19 Vaccines against the B.1.617.2 \(Delta\) Variant](#)
- 2) [Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence](#)
- 3) [Efficacy of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: A test-negative case-control real-world study](#)
- 4) [Effectiveness of COVID-19 vaccines against variants of concern in Ontario, Canada](#)
- 5) [Effectiveness of BNT162b2 Vaccine against Delta Variant in Adolescents](#)
- 6) [A RCT of a third dose CoronaVac or BNT162b2 vaccine in adults with two doses of CoronaVac](#)
- 7) [Effectiveness of BNT162b2 Vaccine against Delta Variant in Adolescents](#)
- 8) [Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa](#)
- 9) [Effectiveness of mRNA-1273 against SARS-CoV-2 omicron and delta variants](#)
- 10) [Covid-19 Vaccine Effectiveness against the Omicron \(B.1.1.529\) Variant](#)
- 11) [Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar](#)

3. Latest Relevant Articles

- [Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial](#)
- [Neutralization Escape by the SARS-CoV-2 Omicron Variants BA.2.12.1 and BA.4/BA.5](#)
- [Real-world effectiveness of molnupiravir and nirmatrelvir/ritonavir among COVID-19 inpatients during Hong Kong's Omicron BA.2 wave: an observational study](#)

- [Impact of the Use of Oral Antiviral Agents on the Risk of Hospitalisation in Community COVID-19 Patients](#)
- [Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study](#)
- [Omicron Infection Induces Low-Level, Narrow-Range SARS-CoV-2 Neutralizing Activity](#)
- [Limited cross-variant immunity from SARS-CoV-2 Omicron without vaccination](#)

4. Other Information

- [FDA Expands Eligibility for Pfizer-BioNTech COVID-19 Vaccine Booster Dose to Children 5 through 11 Years](#)
- [Pfizer-BioNTech COVID-19 Vaccine Demonstrates Strong Immune Response, High Efficacy and Favorable Safety in Children 6 Months to Under 5 Years of Age Following Third Dose](#)
- [FDA panel sets June 15 meeting on Pfizer, Moderna Covid vaccines for infants and toddlers](#)
- [CDC: Rates of COVID-19 Cases and Deaths by Vaccination Status\(updated on May 20, 2022\)](#)
- [UKHSA: SARS-CoV-2 variants of concern and variants under investigation in England Technical briefing 42\(updated on 20 May 2022\)](#)